findmyKOL
Clinical trialNCT06274528RecruitingPhase 2Interventional

DORA and LP in Alzheimer's Disease Biomarkers

SponsorUniversity of MinnesotaEnrollment201Alzheimer Disease
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the blood. Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Washington University in St. Louis, School of Medicine

    St Louis, Missouri, United States

    Brendan P. Lucey, M.D.David Carr, M.D.J. Philip Miller, Ph.D.Jason Hassenstab, Ph.D.
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Mar 2024
Primary completion
31 Mar 2030
Completion
31 Mar 2030
Last update posted
13 Jul 2026
Registered enrollment
201
Registry id
NCT06274528

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.